{"id":519677,"date":"2025-08-08T00:00:00","date_gmt":"2025-08-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0175-biopharma-eosinophilic-esophagitis-epidemiology-mature-markets\/"},"modified":"2026-04-24T05:11:43","modified_gmt":"2026-04-24T05:11:43","slug":"epidim0175-biopharma-eosinophilic-esophagitis-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0175-biopharma-eosinophilic-esophagitis-epidemiology-mature-markets\/","title":{"rendered":"Eosinophilic Esophagitis &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of eosinophilic esophagitis (<abbr title=\"eosinophilic esophagitis\">EoE<\/abbr>) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of <abbr title=\"eosinophilic esophagitis\">EoE<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"eosinophilic esophagitis\">EoE<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"eosinophilic esophagitis\">EoE<\/abbr>?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"eosinophilic esophagitis\">EoE<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts five <abbr title=\"eosinophilic esophagitis\">EoE<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases<\/li>\n<li>Diagnosed prevalent cases by phenotypes<\/li>\n<li>Diagnosed prevalent cases with comorbid allergic rhinitis<\/li>\n<li>Diagnosed prevalent cases with comorbid asthma<\/li>\n<li>Diagnosed prevalent cases with comorbid atopic dermatitis<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-519677","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519677\/revisions"}],"predecessor-version":[{"id":519953,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/519677\/revisions\/519953"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=519677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}